Phase II equivalent Nasal Allergen Challenge (NAC) trial evaluating the tolerability and preliminary efficacy of intranasal MRX 4
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2010
At a glance
- Drugs MRX 4 (Primary) ; Budesonide
- Indications Allergic rhinitis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Celsus Therapeutics
- 16 Jun 2010 Secondary endpoint 'Symptoms' has been met.
- 16 Jun 2010 Secondary endpoint 'Eosinophil count' has been met.
- 16 Jun 2010 Secondary endpoint 'Inflammatory markers' has been met.